HC Wainwright Forecasts Weaker Earnings for Tyra Biosciences

Tyra Biosciences, Inc. (NASDAQ:TYRA) – Investment analysts at HC Wainwright cut their Q1 2025 EPS estimates for Tyra Biosciences in a research report issued on Monday, March 31st. HC Wainwright analyst M. Kapoor now forecasts that the company will post earnings of ($0.56) per share for the quarter, down from their prior estimate of ($0.53). HC Wainwright has a “Buy” rating and a $30.00 price objective on the stock. The consensus estimate for Tyra Biosciences’ current full-year earnings is ($1.57) per share. HC Wainwright also issued estimates for Tyra Biosciences’ Q2 2025 earnings at ($0.58) EPS, Q3 2025 earnings at ($0.60) EPS, Q4 2025 earnings at ($0.63) EPS and FY2025 earnings at ($2.37) EPS.

Other equities analysts have also recently issued reports about the stock. UBS Group started coverage on shares of Tyra Biosciences in a research note on Tuesday, January 7th. They issued a “buy” rating and a $28.00 price objective on the stock. Wedbush reaffirmed an “outperform” rating and issued a $30.00 price objective on shares of Tyra Biosciences in a report on Friday, March 28th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $30.83.

Tyra Biosciences Trading Down 6.7 %

NASDAQ:TYRA opened at $7.74 on Thursday. Tyra Biosciences has a 12-month low of $7.52 and a 12-month high of $29.60. The stock’s 50 day simple moving average is $11.72 and its 200-day simple moving average is $15.94. The firm has a market cap of $391.67 million, a P/E ratio of -4.81 and a beta of 1.09.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.43) EPS for the quarter, beating the consensus estimate of ($0.48) by $0.05.

Insider Transactions at Tyra Biosciences

In related news, Director Nina S. Kjellson sold 5,401 shares of the company’s stock in a transaction that occurred on Wednesday, February 5th. The stock was sold at an average price of $13.76, for a total value of $74,317.76. Following the sale, the director now owns 443,885 shares of the company’s stock, valued at approximately $6,107,857.60. This represents a 1.20 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 21,998 shares of company stock valued at $344,818 in the last 90 days. 15.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Tyra Biosciences

A number of institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP raised its stake in Tyra Biosciences by 4.4% in the 4th quarter. Wellington Management Group LLP now owns 94,859 shares of the company’s stock valued at $1,319,000 after purchasing an additional 4,034 shares during the last quarter. Polar Asset Management Partners Inc. boosted its holdings in shares of Tyra Biosciences by 26.1% during the fourth quarter. Polar Asset Management Partners Inc. now owns 111,107 shares of the company’s stock worth $1,544,000 after purchasing an additional 23,007 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its stake in Tyra Biosciences by 41.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 35,635 shares of the company’s stock valued at $495,000 after purchasing an additional 10,426 shares during the last quarter. Vestal Point Capital LP purchased a new position in Tyra Biosciences during the fourth quarter worth about $13,761,000. Finally, Squarepoint Ops LLC purchased a new stake in Tyra Biosciences in the 4th quarter valued at about $253,000. 84.14% of the stock is owned by institutional investors and hedge funds.

Tyra Biosciences Company Profile

Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.